Utilidad de los marcadores bioquímicos de preeclampsia

Tranquilli, 2014, The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP, Pregnancy Hypertens., 4, 97, 10.1016/j.preghy.2014.02.001 Parker, 2014, Epidemiology of ischemic placental disease: A focus on preterm gestations, Semin Perinatol., 38, 133, 10.1053/j.semperi.2014.03.004 Steegers, 2010, Pre-eclampsia, Lancet, 376, 631, 10.1016/S0140-6736(10)60279-6 Li, 2016, An analysis of the differences between early and late preeclampsia with severe hypertension, Pregnancy Hypertens., 6, 47, 10.1016/j.preghy.2015.12.003 Lisonkova, 2013, Incidence of preeclampsia: Risk factors and outcomes associated with early- versus late-onset disease, Am J Obstet Gynecol., 209, 544.e1, 10.1016/j.ajog.2013.08.019 Ghulmiyyah, 2012, Maternal mortality from preeclampsia/eclampsia, Semin Perinatol., 36, 56, 10.1053/j.semperi.2011.09.011 Auger, 2016, Secular trends in preeclampsia incidence and outcomes in a large Canada database: A longitudinal study over 24 years, Can J Cardiol., 32, 10.1016/j.cjca.2015.12.011 Duley, 2009, The global impact of pre-eclampsia and eclampsia, Semin Perinatol., 33, 130, 10.1053/j.semperi.2009.02.010 Cortés, 2009, Epidemiología de los estados hipertensivos del embarazo, Clin Invest Gin Obst., 36, 132 Comino, 1987, Los estados hipertensivos del embarazo en nuestro país, Prog Obstet Ginecol., 30, 73 NICE Guidance, 2016 [último acceso 27 Feb 2018]. Disponible en: https://www.nice.org.uk/guidance/dg23/chapter/1-Recommendations Pettit, 2012, The management of pre-eclampsia: What we think we know, Eur J Obstet Gynecol Reprod Biol., 160, 6, 10.1016/j.ejogrb.2011.09.049 Staff, 2013, Redefining preeclampsia using placenta-derived biomarkers, Hypertension., 61, 932, 10.1161/HYPERTENSIONAHA.111.00250 Paré, 2014, Clinical risk factors for preeclampsia in the 21st Century, Obstet Gynecol., 124, 763, 10.1097/AOG.0000000000000451 Report of the American College of Obstetricians and Gynecologists. Hypertension in Pregnancy. Am J Obstet Gynecol. 2013; 122:5. Protocolos SEGO. Prog Obstet Ginecol. 2007; 50:446-55. Sibai, 2009, Diagnosis and management of atypical preeclampsia/eclampsia, Am J Obstet Gynecol., 200, 481.e1, 10.1016/j.ajog.2008.07.048 Wright, 2016, Maternal serum PAPP-A and free β-hCG at 12, 22 and 32 weeks’ gestation in screening for pre-eclampsia, Ultrasound Obstet Gynecol., 47, 762, 10.1002/uog.15849 Boyd, 2013, Associations of personal and family preeclampsia history with the risk of early-, intermediate- and late-onset preeclampsia, Am J Epidemiol., 178, 1611, 10.1093/aje/kwt189 Herraiz, 2015, Angiogenesis related biomarkers (sFlt-1/PlFG) in the prediction and diagnosis of placental dysfunction: An approach for clinical integration, Int J Mol Sci., 16, 19009, 10.3390/ijms160819009 Wang, 2010 Andraweera, 2012, The vascular endothelial growth factor family in adverse pregnancy outcomes, Hum Reprod Update., 18, 436, 10.1093/humupd/dms011 Sela, 2008, A novel human-specific soluble vascular endothelial growth factor receptor 1: Cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia, Circ Res., 102, 1566, 10.1161/CIRCRESAHA.108.171504 Circar, 2015, Pathogenesis of preeclampsia, Curr Opin Nephrol Hypertens., 24, 131, 10.1097/MNH.0000000000000105 Venkatesha, 2006, Soluble endoglin contributes to the pathogenesis of preeclampsia, Nat Med., 12, 642, 10.1038/nm1429 Gregory, 2014, The enigmatic role of endoglin in the placenta, Placenta., 35, S93, 10.1016/j.placenta.2013.10.020 Khalil, 2014, Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk of preeclampsia, Ultrasound Obstet Gynecol., 44, 402, 10.1002/uog.13439 Duckwroth, 2016, Diagnosis biomarkers in woman with suspected preeclampsia in a prospective multicenter study, Obstet Gynecol., 128, 245, 10.1097/AOG.0000000000001508 Anderson, 2012, Review: Biochemical markers to predict preeclampsia, Placenta., 33 Suppl, S42, 10.1016/j.placenta.2011.11.021 Levine, 2004, Circulating angiogenic factors and the risk of preeclampsia, N Engl J Med., 350, 672, 10.1056/NEJMoa031884 Andersen, 2015, Diagnosis of pre-eclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison, J Am Soc Hypertens., 9, 86, 10.1016/j.jash.2014.11.008 Sibai, 2005, Pre-eclampsia, Lancet, 365, 785, 10.1016/S0140-6736(05)17987-2 Poon, 2014, Early prediction of preeclampsia, Obstet Gynecol Int., 2014, 297397, 10.1155/2014/297397 North, 2011, Clinical risk prediction for pre-eclampsia in nulliparous women: Development of model in international prospective cohort, BMJ., 342, d1875, 10.1136/bmj.d1875 Leslie, 2011, Early prediction and prevention of pre-eclampsia, Best Pract Res Clin ObstetGynaecol., 25, 343, 10.1016/j.bpobgyn.2011.01.002 Zhong, 2015, Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: Systematic review and meta-analysis, BMC Pregnancy Childbirth., 15, 191, 10.1186/s12884-015-0608-y Nucci, 2014, Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13 weeks’ gestation in normal and pathological pregnancies, Fetal Diagn Ther., 36, 106, 10.1159/000357842 Wu, 2015, Early pregnancy biomarkers in pre-eclampsia: A systematic review and meta-analysis, Int J Mol Sci., 16, 23035, 10.3390/ijms160923035 Poon, 2009, First-trimester prediction of hypertensive disorders in pregnancy, Hypertension., 53, 812, 10.1161/HYPERTENSIONAHA.108.127977 Akolekar, 2013, Competing risks model in early screening for preeclampsia by biophysical and biochemical markers, Fetal DiagnTher., 33, 8, 10.1159/000341264 Verma, 2016, MoM cutoffs for variables, an important tool for multivariate analysis and accurate interpretation of preeclampsia risk in high-risk at 11-13+6 weeks gestation, Hypertens Pregnancy., 35, 548, 10.1080/10641955.2016.1211675 Perucci, 2014, Soluble endoglin transforming growth factor-beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia, PLoS One., 5, e97632, 10.1371/journal.pone.0097632 Seravalli, 2016, Relationship between first-trimester serum placental protein-13 and maternal characteristics, placental Doppler studies and pregnancy outcome, J Perinat Med., 44, 543, 10.1515/jpm-2015-0324 O’Gorman, 2016, Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation, Am J Obstet Gynecol., 214, 10.1016/j.ajog.2015.08.034 O’Gorman, 2017, Accuracy of competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation, Ultrasound Obstet Gynecol., 49, 751, 10.1002/uog.17399 Escudero, 2016, Role of extracellular vesicles and microRNAs on dysfunctional angiogenesis during preeclamptic pregnancies, Front Physiol., 7, 98, 10.3389/fphys.2016.00098 Li, 2013, Maternal plasma miRNAs expression in preeclamptic pregnancies, Biomed Res Int., 2013, 970265, 10.1155/2013/970265 Chappell, 2013, Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: A prospective multicenter study, Circulation., 128, 2121, 10.1161/CIRCULATIONAHA.113.003215 Stepan, 2007, Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion, Hypertension., 49, 818, 10.1161/01.HYP.0000258404.21552.a3 Stubert, 2014, Prediction of preeclampsia and induced delivery at <34 weeksgestation by sFlT-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: A prospective cohort analysis, BMC Pregnancy Childbirth., 14, 292, 10.1186/1471-2393-14-292 Verlohren, 2014, New gestational phase-specific cut-off values for the use of soluble fms-like tyrosine kinase-1/placental growth factor ratio as diagnostic test for preeclampsia, Hypertension., 63, 346, 10.1161/HYPERTENSIONAHA.113.01787 Álvarez-Fernández, 2014, New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis, Clin Chem Lab Med., 52, 1159, 10.1515/cclm-2013-0901 Stepan, 2015, Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: Implications for clinical practice, Ultrasound Obstet Gynecol., 45, 241, 10.1002/uog.14799 Zeisler, 2016, Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia, N Engl J Med., 374, 13, 10.1056/NEJMoa1414838 Gallo, 2016, Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks’ gestation, Am J Obstet Gynecol., 214, e1, 10.1016/j.ajog.2015.11.016 Tan, 2017, Comparison of screening for preeclampsia at 31-34 weeks’ gestation by the sFlT-1 to PlGF ratio and a method combining maternal factors with sFlT-1 and PlGF, Ultrasound Obstet Gynecol., 49, 201, 10.1002/uog.17307 Tsiakkas, 2016, Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks’ gestation, Am J Obstet Gynecol., 215, 87.e1, 10.1016/j.ajog.2016.02.016 Tsiakkas, 2015, Serum placental growth factor in the three trimesters of pregnancy: Effects of maternal characteristics and medical history, Ultrasound Obstet Gynecol., 45, 591, 10.1002/uog.14811 Wright, 2016, Contingent screening for preterm pre-eclampsia, Ultrasound Obstet Gynecol., 47, 554, 10.1002/uog.15807 Zhao, 2017, Dual-cutoff of sFlt-1/PLGF ratio in the stratification of preeclampsia: A systematic review and meta-analysis, Arch Gynecol Obstet., 295, 1079, 10.1007/s00404-017-4302-3 Meads, 2008, Methods of prediction and prevention of preeclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling, Health Technol Assess., 12, 1, 10.3310/hta12060 Schnettler, 2013, Cost and resource implications with serum angiogenic factor estimation in the triage of preeclampsia, BJOG., 120, 1224, 10.1111/1471-0528.12259 Hadker, 2010, Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: A decision-analytic modeling analysis from a UK healthcare payer perspective, J Med Econ., 13, 728, 10.3111/13696998.2010.535285 Hadker, 2013, Are there financial savings associated with supplementing current diagnostic practice for preeclampsia with a novel test? Learnings from a modeling analysis from a German payer perspective, Hypertens Pregnancy., 32, 105, 10.3109/10641955.2011.638958 Duckworth, 2016, Placental growth factor (PlGF) inwomen with suspected pre-eclampsia prior to 35 weeks’ gestation: A budget impact analysis, PLoS One., 11, e0164276, 10.1371/journal.pone.0164276 Shmueli, 2012, Economic assessment of screening of preeclampsia, Prenat Diag., 32, 29, 10.1002/pd.2871 Zakiyah, 2015, Pre-eclampsia diagnosis and treatment options: A review of published economic assessments, Pharmacoeconomics, 33, 1069, 10.1007/s40273-015-0291-x Zakiyah, 2014, Economic assessment of preeclampsia: Screening, diagnosis, treatment options, and long term outcomes – A systematic review, Value Health., 17, A506, 10.1016/j.jval.2014.08.1544 Third addendum (28th January 2016) covering the EAG's response to consultation on the second Diagnostics Consultation Document. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: Systematic review and economic analysis. NICE Guidance. 2016 [último acceso 27 Feb 2018]. Disponible en: https://www.nice.org.uk/guidance/dg23/chapter/1-Recommendations Resource impact report: PlGF-basedtesting to help diagnose suspectedpre-eclampsia (Triage PlGF test, Elecsysimmunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio)(DG23). NICE Guidance [último acceso 27 Feb 2018]. Disponible en: https://www.nice.org.uk/guidance/dg23/resources Herraiz, 2018, Update on the diagnosis and prognosis of preeclampsia with the aid of sFlt-1/PLGF ratio in singleton pregnancies, Fetal DiagnTher, 43, 81, 10.1159/000477903 Roberge, 2017, The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: Systematic review and meta-analysis, Am J Obstet Gynecol., 216, 110, 10.1016/j.ajog.2016.09.076 Roberge, 2016, Low-dose aspirin in early gestation for prevention of preeclampsia and small-for-gestational-age neonates: Meta-analysis of large randomized trials, Am J Perinatol., 33, 781, 10.1055/s-0036-1572495 Rolnik, 2017, ASPRE trial: Performance of screening for preterm pre-eclampsia, Ultrasound Obst Gynecol., 50, 492, 10.1002/uog.18816 Rolnik, 2017, Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia, N Engl J Med., 377, 613, 10.1056/NEJMoa1704559 Heazell, 2015, Use of biochemical tests of placental function for improving pregnancy outcome, Cochrane Database of Systematic Reviews, Issue11 German guideline [último acceso 27 Feb 2018]. Disponible en: http://www.awmf.org/uploads/tx_szleitlinien/015-018l_S1_Diagnostik_Therapie_hypertensiver_Schwangerschaftserkrankungen_2014-verlaengert.pdf